Iridex to Report First Quarter 2026 Financial Results on May 19, 2026
Iridex (Nasdaq: IRIX) will release first-quarter 2026 financial results and provide a business update after market close on May 19, 2026.
Rhea-AI Summary
Iridex (Nasdaq: IRIX) will release first-quarter 2026 financial results and provide a business update after market close on May 19, 2026. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET with live and recorded webcast access via the company website.
Investors can join by phone using Conference ID 9329659 or listen on the Events page at www.iridex.com.
Positive
- None.
Negative
- None.
Details
News Market Reaction – IRIX
In the May 6 session, IRIX declined 0.95%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings release date
- May 19, 2026
- Q1 2026 financial results and business update
- Conference time PT
- 2:00 p.m. PT
- Start of management conference call
- Conference time ET
- 5:00 p.m. ET
- Start of management conference call
- US dial-in
- +1-646-307-1963
- Investor access to conference call from US
- International dial-in
- +1-800-715-9871
- Investor access to conference call internationally
- Conference ID
- 9329659
- Code required to join earnings conference call
- Quarter reported
- First quarter 2026
- Upcoming financial results being released
Previous Earnings date Reports
-
Set date and call details for Q4 and full-year 2025 results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the first quarter 2026 and provide a business update after the close of trading on May 19, 2026.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and providing Conference ID: 9329659. A live and recorded webcast will be available on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices, and accessories for the ophthalmology market. The Company’s technologies are used in the treatment of glaucoma, diabetic macular edema, and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.